Lux Biosciences to Provide Update on Four Pipeline Programs, Including Two Phase 3 Clinical Programs, at ARVO
We also will be presenting highly original work with bioerodible polymers as well as a clear, mixed micellar formulation for ocular delivery of our next generation calcineurin inhibitor (LX212 and LX214, respectively). These latter two product candidates are tailor-made for dry eye and other, highly prevalent chronic inflammatory diseases of the eye.”
Further blurb on LX214:
LX214, a novel topical eye drop formulation currently in IND-enabling studies with a target date for entry into the clinic in mid 2008. LX214 is based on Lux’ proprietary next-generation calcineurin inhibitor and is targeted towards other chronic inflammatory diseases of the eye, most notably dry eye syndrome, blepharitis and atopic keratoconjunctivitis.
1 comment:
While it's nice that there are many agents to choose from when seeking relief from dry eye, I think the pharmaceutical industry should focus on research into the causes of dry eye, such as Sjogren's, and the development of agents that slow or stop the progression of the condition rather than the development of more "me-too" agents that are easy and less expensive to develop but less valuable to patients in the long run.
Post a Comment